

To,

Date: 19.05.2022

1. BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2. Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400098
---	---

Dear Sir/Madam,

Sub: Outcome of board meeting held on 19.05.2022

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of DrHabeebullah Life Sciences Limited held on Thursday, the 19th day of May, 2022 at 3:30 p.m. at the registered office of the Company, the following were considered and approved by the Board:

1. Audited financial results for the quarter and year ended 31.03.2022.
2. Audit Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022.


The meeting concluded at 4.30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Sincerely,

For Dr Habeebullah Life Sciences Limited




K.Krishnam Raju
Chairman & Whole-Time Director
(DIN: 00874650)

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082
.CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com
Contact No.: 9490424639, Website : www.drhsl.com

PART II - AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH, 2022						
(INR In Lakhs)						
		Quarter Ended			Year Ended	
		3 Months Ended 31/03/2022	Preceeding 3 Months Ended 31/12/2021	Corsp. 3 months ended 31/03/2021	31/03/2022	31/03/2021
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	2.25	-	-	2.25	1.30
II	Other Income	178.44	4.17	3.85	190.62	14.77
III	Total Revenue (I+II)	180.69	4.17	3.85	192.87	16.07
IV	Expenses					
	Purchases	2.16	-	-	2.16	-
	Cost of Material Consumed	-	-	-	-	0.19
	Changes in inventories	12.92	-	-	12.92	-
	Employee benefits expense	5.28	2.76	0.78	11.47	33.17
	Depreciation and Amortisation expense	0.13	0.13	0.17	0.54	0.96
	Other Expenses	2.33	2.95	5.01	15.94	58.72
	Total Expenses	22.82	5.84	5.96	43.03	93.04
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	157.87	(1.67)	(2.11)	149.84	(76.97)
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	157.87	(1.67)	(2.11)	149.84	(76.97)
VIII	Tax Expense:					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	157.87	(1.67)	(2.11)	149.84	(76.97)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)					
XIII	Profit/ (Loss) for the period (IX+XII)	157.87	(1.67)	(2.11)	149.84	(76.97)
XIV	Other Comprehensive Income					
	A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss					
	(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to	-	-	12.67	-	14.08
XV	period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	157.87	(1.67)	10.56	149.84	(62.89)
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-	-
XVII	Comprehensive Income attributable to Owners of the company	157.87	(1.67)	10.56	149.84	(62.89)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
	1) Basic	1.07	(0.01)	0.07	1.01	(0.42)
	2) Diluted	1.07	(0.01)	0.07	1.01	(0.42)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic					
	2) Diluted	-	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
	1) Basic	1.07	(0.01)	0.07	1.01	(0.42)
	2) Diluted	1.07	(0.01)	0.07	1.01	(0.42)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87	1,480.87




Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Thursday, May 19th, 2022.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. During this Quarter the company has restarted the business as per objects in a small way and expected to enter the Bio-Pharma business in the coming months.
4. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
5. The figures of the current quarter ended March 31, 2022 and the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
6. The Company has only one reportable segment i.e., **Heath Care** Sector. Hence, the separate disclosure on Segment information is not required.
7. The results are also available on the webiste of the Company www.drhlsl.com


For DR HABEEBULLAH LIFE SCIENCES LIMITED

K Krishnam Raju
Executive Chairman (DIN 00874650)

Place : Hyderabad
Date: 19/05/2022




DR Habeebullah Life Sciences Limited		
Statement of Assets and Liabilities		
(INR. in Lakhs)		
Particulars	STANDALONE	
	31/03/2022	31/03/2021
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	1.25	1.79
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	325.95	325.95
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
i Investments	487.06	487.06
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	200.25	203.99
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	-	-
Total Non Current Assets	1,014.51	1,018.79
2 Current Assets		
a Inventories	-	12.92
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	212.45	214.26
iii Cash and Cash Equivalents	0.93	0.41
iv Bank balances other than above	-	-
v Loans and Advances	134.00	134.00
vi Other financial assets	52.59	37.77
c Current Tax Assets (net)	-	-
d Other Current Assets	305.54	304.39
Total Current Assets	705.51	703.75
Total Assets	1,720.02	1,722.53
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(150.99)	(300.83)
iii Non-Controlling Interests	-	-
Total - Equity	1,329.88	1,180.04



2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	7.08	4.56
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	7.08	4.56
Current Liabilities		
a Financial Liabilities		
i Borrowings	274.07	234.05
ii Trade Payables	12.15	28.72
iii Other Financial Liabilities	-	-
b Other Current Liabilities	96.83	275.15
c Provisions	0.00	0.00
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	383.06	537.93
Total - Equity and Liabilities	1,720.02	1,722.53

For DR HABEEBULLAH LIFE SCIENCES LIMITED

[Handwritten Signature]



Place: Hyderabad

Date: 19/05/2022

K. Krishnam Raju
Executive Chairman (DIN 00874650)

DR HABEEBULLAH LIFE SCIENCES LIMITED
6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta
Hyderabad 500082, Telangana State, INDIA

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2022

(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2022	Year Ended March 31, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	14,983,901	(6,288,573)
Adjustment for:		
Depreciation and Amortisation	53,611	96,014
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	<u>15,037,512</u>	<u>(6,192,559)</u>
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	180,302	325,722
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(115,047)	(7,173)
(Increase)/ Decrease in other other financial Assets	(1,481,780)	(1,366,531)
(Increase)/ Decrease in Inventories	1,292,128	19,273
Increase /(Decrease) in Trade Payables	(1,657,004)	(177,649)
Increase/ (Decrease) in Other current liabilities	(17,831,926)	5,195,363
Increase/ (Decrease) in Current Provisions	(96)	(242,944)
Change in Working Capital	<u>(19,613,423)</u>	<u>3,746,061</u>
Changes in non current assets and liabilities		
Decrease/(Increase) in other financials Assets	373,662	29,000
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	252,146	(993,399)
Changes in non current assets and liabilities	<u>625,808</u>	<u>(964,399)</u>
Cash Generated From Operations	(3,950,103)	(3,410,897)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	<u>(3,950,103)</u>	<u>(3,410,897)</u>
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increases) / Decrease in Fixed assets and Capital Work In progress	-	(2,272,849)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	<u>-</u>	<u>(2,272,849)</u>
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	4,002,000	5,490,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	<u>4,002,000</u>	<u>5,490,000</u>
D. Effect of exchange differences on translation of foreign currency cash and	-	-
Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	51,897	(193,745)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	41,317	235,061
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	<u>93,213</u>	<u>41,317</u>

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

(K. Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Place: Hyderabad
Date : 19/05/2022

To,

Date: 19.05.2022

1.BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2.Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400098
--	---

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, K. Krishnam Raju, Chairman & Whole-time Director of Dr Habeebullah Life Sciences Limited hereby declare that the statutory Auditors of the company, M/s. A.M. Reddy & D.R. Reddy., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours sincerely,

For DrHabeebullah Life Sciences Limited



K. Krishnam Raju
Chairman & Whole-time Director
DIN: 00874650

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082

.CIN No.: L85110TG1996PLC099198. Email: cs@drhlsl.com, info@drhlsl.com, pcproductsindia@gmail.com

Contact No.: 9490424639, Website : www.drhlsl.com



A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly Financial Results and Year to Date Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of Dr Habeebullah Life Sciences Limited

Report on the Audit of Financial Results

Opinion

We have audited the accompanying annual financial results of Dr Habeebullah Life Sciences Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other financial information of the Company for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Financial Results

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.


As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The Statement include the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.


The Annual Financial results dealt with by this report have been prepared for the express purpose of filing with stock exchanges on which company shares are listed. These results are based on should be read with the audited financial statements of the company for the year ended March 31, 2022.

Our Opinion is not modified in respect of the above matter.

For A.M REDDY & D.R REDDY

Chartered Accountants

ICAI Firm Registration No.0090685



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 22209211AJGLBW9448

Place: Hyderabad

Date: May 19, 2022

